Resource for Molecular Imaging Agents in Precision Medicine

精准医学分子成像剂资源

• 批准号: 10226206
• 负责人: MARTIN G POMPER
• 金额: $ 117.95万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-09-15 至 2024-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10226206
• 关键词: Address; Autologous Transplantation; Biological; Biological Markers; Biomedical Technology; Brain imaging; CAR T cell therapy; Cancer Vaccines; Caring; Cell Line; Cell Transplantation; Cell surface; Cells; Chemical Agents; Chemicals; Chemistry; Clinic; Clinical; Collaborations; Communities; Data; Detection; Development; Discipline of Nuclear Medicine; Education; Environment; FOLH1 gene; Generations; Genetic; Genetically Engineered Mouse; Goals; Grant; Hand; Histopathology; Human; Image; Immersion; Immunity; Immunohistochemistry; Immunooncology; Immunotherapy; Industry; Inflammation; Inflammatory; Infrastructure; Institutes; Investments; Journals; Libraries; Link; Location; Malignant Neoplasms; Medical; Methods; Mission; Molecular Genetics; National Institute of Biomedical Imaging and Bioengineering; New Agents; Organic Synthesis; Patient Care; Patients; Peptides; Peptoids; Pharmacology; Phenotype; Positron-Emission Tomography; Preclinical Testing; Process; Radiology Specialty; Reagent; Recording of previous events; Reporter; Research; Resources; Schools; Services; Site; System; Technical Expertise; Technology; Training; Transgenic Organisms; Translating; Translations; United States National Institutes of Health; Universities; Validation; Work; anticancer research; arm; cancer cell; cancer imaging; cancer immunotherapy; cellular imaging; commercialization; cost; design; flexibility; handicapping condition; human imaging; imaging agent; imaging modality; imaging system; immune checkpoint; in vitro Model; in vivo; in vivo monitoring; instrumentation; lectures; molecular imaging; neuroinflammation; next generation; nuclear division; phase II trial; pre-clinical; precision medicine; programs; radioligand; radiotracer; research and development; side effect; small molecule; targeted agent; technology development; theranostics; tumor; tumor microenvironment; web site

OVERALL RESOURCE: Summary The Resource for Molecular Imaging Agents in Precision Medicine is a program spanning three campuses of the Johns Hopkins University (JHU). In our view precision medicine is using all data at hand regarding a particular patient to enable the best possible care for that patient. We believe that carefully designed molecular imaging agents can contribute to this. We are now poised to offer a unique Biomedical Technology Resource Center (BTRC) with a heavy emphasis on the provision of chemistry – new reagents, methods and training in their development and practice – for molecular imaging. The biological theme of the BTRC is relationships between cancer, inflammation and immunity, deeper study of which is an unmet need. Although brilliant research continues worldwide in the development of new molecular imaging agents, few have had actual impact on addressing human infirmity and many do not justify the cost of their development. In March 2014 the NIBIB conducted a study “to better understand the reasons why more molecular imaging agents and instrumentation developed with NIH grant support are not being translated to the clinic nor subsequently commercialized.” To address those shortcomings, the JHU BTRC will be highly translational by leveraging the Center for Translational Molecular Imaging (CTMI) at the Johns Hopkins Bayview medical campus, the F. M. Kirby Center for Functional Brain Imaging at the Kennedy Krieger Institute, the Division of Cancer Imaging Research, and the Division of Nuclear Medicine and Molecular Imaging, all of which are highly integrated into numerous departments and schools at JHU. We have generated agents that have been licensed and are in the process of commercialization. However to date those activities have been performed on an ad hoc basis, and we intend to expand upon them in two new ways: (1) provide targeted and unique technical research and development (TR&D) projects that will (2) enable widespread dissemination and training in their use, enhancing the capacity of the centers and divisions noted above to perform their intended functions – discovery with intent to educate, promote new collaborative, transdisciplinary research and to manage a variety of conditions, while addressing unanticipated effects of emerging cancer immunotherapies. The unique aspect of the BTRC is its focus on provision of new, precision materials, to test these pre-clinically and progress them to human use, delivered on-site or to our collaborators in a format suitable for their implementation. We will assure proper off-site utilization through continual, reciprocal education and “push-pull” interactions. The program is agnostic to imaging modality and composition of the materials to provide, relying upon the specific expertise within each TR&D. In addition to sharing the goal of leveraging chemistry for imaging, the four TR&Ds will be linked through the aforementioned biological theme. They can briefly be summarized as focusing on new theranostics (TR&D 1), molecular-genetic imaging systems (TR&D 2), agents for probing immunity (TR&D 3), and targeted agents for chemical exchange saturation transfer (CEST, TR&D 4). Within TR&Ds 1 and 3 are also the Pre-clinical and Clinical Validation cores, respectively.

总体资源：摘要 精准医学中分子成像剂的资源是一个跨越三个校区的计划， 约翰霍普金斯大学。在我们看来，精准医疗是利用手头上的所有数据， 患者，为患者提供最好的护理。我们相信精心设计的分子成像 代理商可以为此做出贡献。我们现在准备提供独特的生物医学技术资源中心 （BTRC），重点是提供化学-新试剂，方法和培训， 发展和实践-用于分子成像。BTRC的生物学主题是 癌症，炎症和免疫，对这些疾病的深入研究是一个未满足的需求。虽然出色的研究 在世界范围内继续开发新的分子成像剂，很少有实际的影响， 解决人类的弱点和许多弱点并不能证明其发展的成本是合理的。2014年3月，NIBIB 进行了一项研究，“以更好地了解为什么越来越多的分子成像剂和仪器， 在NIH的资助下开发的药物没有被转化为临床药物，也没有随后被商业化。到 为了解决这些缺点，JHU BTRC将通过利用翻译中心， 分子成像（CTMI）在约翰霍普金斯湾景医学院，F。M.柯比功能中心 脑成像在肯尼迪克里格研究所，癌症成像研究部， 核医学和分子成像，所有这些都高度集成到许多部门， 学校在JHU。我们已经生成了已获得许可并正在商业化的代理。 然而，迄今为止，这些活动是临时性的，我们打算扩大这些活动 以两种新的方式：（1）提供有针对性的和独特的技术研究和发展（TR&D）项目， (2)使其能够广泛传播和培训，提高各中心和部门的能力 如上所述，以执行其预期的功能-发现，旨在教育，促进新的合作， 跨学科研究和管理各种条件，同时解决意外的影响， 新兴的癌症免疫疗法。BTRC的独特之处在于它专注于提供新的，精确的 材料，以在临床前测试这些材料并将其用于人类使用，现场交付或交付给我们的合作者 以适合于其实施格式。我们将通过持续的、互惠的、 教育和“推拉”互动。该计划是不可知的成像方式和组成， 根据每个TR&D内的特定专业知识提供材料。除了分享目标之外， 利用化学成像，四个TR& D将通过上述生物主题联系起来。 他们可以简要地概括为新的治疗诊断学（TR&D 1），分子遗传成像系统 (TR免疫探测剂（TR&D 3）和化学交换饱和转移靶向剂 (CEST，TR&D 4）。TR& D 1和3中还分别包含临床前和临床验证核心。

项目成果

Acoustic-resolution photoacoustic microscope based on compact and low-cost delta configuration actuator.

• DOI: 10.1016/j.ultras.2021.106549
• 发表时间: 2022-01
• 期刊: Ultrasonics
• 影响因子: 4.2
• 作者: Gao S;Tsumura R;Vang DP;Bisland K;Xu K;Tsunoi Y;Zhang HK
• 通讯作者: Zhang HK

Carbon Dots as a New Class of Diamagnetic Chemical Exchange Saturation Transfer (diaCEST) MRI Contrast Agents.

• DOI: 10.1002/anie.201904722
• 发表时间: 2019-06
• 期刊: Angewandte Chemie
• 作者: Jia Zhang;Yue Yuan;Minling Gao;Zheng Han;Chengyan Chu;Yuguo Li;P. V. van Zijl;M. Ying;J. Bulte;Guanshu Liu

6-O-(2-[18F]Fluoroethyl)-6-O-Desmethyl-Diprenorphine ([18F]FE-DPN) Preferentially Binds to Mu Opioid Receptors In Vivo.

6-O-(2-[18F]氟乙基)-6-O-去甲基-二丙诺啡 ([18F]FE-DPN) 在体内优先与 Mu 阿片受体结合。

• DOI: 10.1007/s11307-022-01767-5
• 发表时间: 2023
• 期刊: Molecular imaging and biology
• 影响因子: 3.1
• 作者: Levinstein,MarjorieR;Ventriglia,EmilyaN;Gomez,JuanL;Budinich,ReeceC;Marton,János;Henriksen,Gjermund;Holt,DanielP;Dannals,RobertF;Pomper,MartinG;ZarateJr,CarlosA;Bonaventura,Jordi;Michaelides,Michael
• 通讯作者: Michaelides,Michael

A Unique Core-Shell Structured, Glycol Chitosan-Based Nanoparticle Achieves Cancer-Selective Gene Delivery with Reduced Off-Target Effects.

• DOI: 10.3390/pharmaceutics14020373
• 发表时间: 2022-02-07
• 期刊: Pharmaceutics
• 影响因子: 5.4
• 作者: Cheng B;Ahn HH;Nam H;Jiang Z;Gao FJ;Minn I;Pomper MG
• 通讯作者: Pomper MG

Noninvasive assessment of renal dynamics and pH in a unilateral ureter obstruction model using DCE MR-CEST urography.

• DOI: 10.1002/mrm.29436
• 发表时间: 2023-01
• 期刊: Magnetic resonance in medicine
• 影响因子: 3.3